Summary
The technology for plant-made pharmaceuticals (PMPs) has progressed significantly over the last few years, with the first commercial products for human use expected to reach the market by 2009 (see Note 1 ). As part of the ‘next generation’ of genetically modified (GM) crops, PMPs will be subject to additional biosafety considerations and are set to challenge the complex and overlapping regulations that currently govern GM plants, plant biologics (see Note 2 ) and ‘conventional’ pharmaceutical production. The areas of responsibility are being mapped out between the different regulatory agencies (Sparrow, P.A.C., Irwin, J., Dale, P., Twyman, R.M., and Ma, J.K.C. (2007) Pharma-Planta: Road testing the developing regulatory guidelines for plant-made pharmaceuticals. Transgenic Res., 2007), with specific guidelines currently being drawn up for the regulation of PMPs. In this chapter, we provide an overview of the biosafety (see Note 3 ), risk assessment (see Note 4 ) and regulation of this emerging technology. While reference will be made to EU regulations, the underlying principles of biosafety and risk assessment are generic to most countries.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Dawson, W. (2005) Herbal medicines and the EU Directive. J. Royal Coll. Phys. Edinburgh 35, 25–27.
ISAAA (2006) Global Status of Commercialized Biotech/GM Crops: 2006. http://www. isaaa.org/.
Spok, A. (2007) Molecular farming on the rise–GMO regulators still walking a tightrope. Trends Biotechnol. 25, 74–82.
CPMP (2002) Points to Consider on Quality Aspects of Medicinal Products Containing Active Substances Produced by Stable Trans-gene Expression in Higher Plants (CPMP/ BWP/764/02). European Agency for the Evaluation of Medicinal Products (EMEA).
FDA (2002) Guidance for Industry. Drugs, Biologics, and Medical Devices Derived from Bioengineered Plants for use in Humans and Animals. Food and Drug Administration.
CPMP (2006) Draft Guideline on the Quality of Biological Active Substances Produced by Stable Transgene Expression in Higher Plants. European Agency for the Evaluation of Medicinal Products (EMEA).
Twyman, R.M., Stoger, E., Schillberg, S., Christou, P., and Fischer, R. (2003) Molecular farming in plants: Host systems and expression technology. Trends Biotechnol. 21, 570–578.
Twyman, R.M., Schillberg, S., and Fischer, R. (2005) Transgenic plants in the biophar-maceutical market. Expert. Opin. Emerg. Drugs 10, 185–218.
Union of Concerned Scientists (2006) UCS Position Paper: Pharmaceutical and Industrial Crops. UCS. http://www.ucsusa.org/food_ and_environment/genetic_engineering/ ucs-position-paper.html
Commandeur, U., Twyman, R.M., and Fischer, R. (2003). The biosafety of molecular farming in plants. AgBiotechNet 5, 1–9.
Dunwell, J. (2005) Technologies for Biological Containment of GM and Non-GM Crops. DEFRA Contract CPEC 47.
Sparrow, P.A.C., Irwin, J., Dale, P., Twyman, R.M., and Ma, J.K.C. (2007) Pharma-Planta: Road testing the developing regulatory guidelines for plant-made pharmaceuticals. Transgenic Res. 16, 147–161.
Spök, A., Twyman, R.M., Fischer, R., Ma, J. K.C., and Sparrow, P.A.C. (2008) Evolution of a regulatory framework for pharmaceuticals derived from genetically modified plants. Trends in Biotech. 26(9): 506–517.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2009 Springer Science+Business Media, LLC
About this protocol
Cite this protocol
Sparrow, P.A., Twyman, R.M. (2009). Biosafety, Risk Assessment and Regulation of Plant-Made Pharmaceuticals. In: Faye, L., Gomord, V. (eds) Recombinant Proteins From Plants. Methods in Molecular Biology™, vol 483. Humana Press. https://doi.org/10.1007/978-1-59745-407-0_20
Download citation
DOI: https://doi.org/10.1007/978-1-59745-407-0_20
Publisher Name: Humana Press
Print ISBN: 978-1-58829-978-9
Online ISBN: 978-1-59745-407-0
eBook Packages: Springer Protocols